# Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo

> **NCT00228462** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 197 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Seroquel (quetiapine)

## Key facts

- **NCT ID:** NCT00228462
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228462, "Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00228462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*